NanoViricides Inc. (NNVC)

[Paulness]

When the cream for the treatment of herpes is sold there is a very big market for it! Topicals are a lot quicker to pass by the FDA that intravenous use.

Despite the availability of small-molecule antiviral treatments, a clear unmet need remains for a range of skin problems caused by infections with herpes viruses. These include cold sores (herpes simplex virus type 1 (HSV-1)), genital ulcers (HSV-2), and shingles, caused by varicella zoster virus (VZV), the same virus responsible for chicken pox. Shingles is both widespread and debilitating. Each year, as many as 20 million people worldwide are affected by shingles, and more than 50,000 people in the United States are hospitalized with shingles or its complications. The skin lesions caused by VZV reactivation are painful, and in some cases they last for months. New, more effective, and ideally topical treatments have the potential to transform therapy by replacing or supplementing nucleoside drugs that are largely ineffective against these diseases